Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe crawled date : 2022 - 05 - 09 save search
Enphase Energy Announces IQ™ Battery Compatibility with Third-Party Inverters in Europe
Published: 2022-05-09 (Crawled : 22:00) - globenewswire.com
ENPH S | $112.075 1.45% 1.43% 3.6M
|
Electronic Technology
|
| O: -3.31%
H: 2.08%
C: -6.17%
battery europe energy
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
Published: 2022-05-09 (Crawled : 14:00) - biospace.com/
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
nanobody disease control trial psoriasis publication phase 2b
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
Published: 2022-05-09 (Crawled : 14:00) - biospace.com/
ACHL | $0.8 -0.27% -0.28% 180K
|
Manufacturing
|
| O: 0.46%
H: 1.84%
C: -9.68%
trial therapeutics enroll
Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)
Published: 2022-05-09 (Crawled : 14:00) - biospace.com/
AKTX | $1.1555 -1.69% 7.9K
|
Health Technology
|
| O: -0.88%
H: 2.68%
C: 0.89%
disease preclinical macular results pre-clinical
Liminal Biosciences to Present at Upcoming Investor Conferences
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
LMNL | $8.5 0.12% 0.12% 0
|
Health Technology
|
| O: -5.67%
H: 6.01%
C: -2.54%
bioscience
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
ADCT | $4.96 11.71% 1.41% 1.2M
|
Health Technology
|
| O: -3.94%
H: 1.1%
C: -28.08%
therapeutics results
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
JAZZ | News | $107.15 -1.61% -1.63% 590K
|
Health Technology
|
| O: -1.4%
H: 0.61%
C: -4.73%
AXSM | $69.69 1.28% 1.26% 400K
|
Health Technology
|
| O: -17.99%
H: 1.48%
C: -7.64%
sunosi therapeutics solriamfetol
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
Published: 2022-05-09 (Crawled : 11:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -10.28%
H: 0.0%
C: 0.0%
orgovyx europe license cancer prostate cancer
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.